Vivos Therapeutics agrees to acquire 11% stake in SOD Sciences
VVOS•Vivos Therapeutics agreed to acquire an 11% fully diluted stake in SOD Sciences and 50% co-ownership of its pseudohypoxia test for preferred shares with a $12 million stated value and no cash payment. Closing is expected on or about October 15, 2026, subject to customary conditions.
1. Deal terms
Vivos Therapeutics agreed to acquire an 11% fully diluted stake in SOD Sciences and 50% co-ownership of its proprietary pseudohypoxia test. Consideration consists of 12,000 Series C Convertible Preferred Stock shares with an aggregate stated value of $12 million; no cash is payable. The preferred shares convert at $0.15 into up to 80 million common shares, subject to a 19.99% exchange cap pending stockholder approval.
2. Expected closing
The transaction is expected to close on or about October 15, 2026, subject to customary conditions. It could increase reported stockholders' equity and support efforts to regain compliance with Nasdaq's minimum equity requirement, subject to accounting review.
